Abeona Therapeutics: Navigating the ZEVASKYN Launch and Financial Landscape

November 12, 2025 | By a seasoned finance analyst

Abeona Therapeutics Inc. (Nasdaq: ABEO) has just dropped its third-quarter financial results, and while the numbers might not leap off the page, the narrative surrounding its flagship product, ZEVASKYN, is anything but dull. Investors are keenly watching the company's EPS consensus as they navigate the complexities of a shifting timeline and regulatory hurdles.

Shifting Timelines and Strong Demand

In a twist that would make even the most seasoned investors raise an eyebrow, Abeona has shifted the anticipated launch of ZEVASKYN patient treatments to the fourth quarter of 2025. This delay stems from the optimization of a release assay that initially yielded a false positive during FDA scrutiny. But don’t let that overshadow the fact that the company has managed to maintain strong patient demand and a growing treatment site network. With $207.5 million in cash and equivalents as of September 30, 2025, Abeona is well-positioned to fund operations for over two years—definitely a cushion for any potential earnings surprise.

Recent Developments: A Closer Look

Despite the shift in timelines, there are several key developments worth noting:

Optimized Product Release: Following a full batch of drug product manufactured in Q3, Abeona has now resumed patient biopsy collections after successfully optimizing the release assay. This is crucial for ensuring reliable results and avoiding future lot rejections.
Growing Patient Demand: Demand for ZEVASKYN has more than doubled at the first two Qualified Treatment Centers (QTCs). With 12 ZEVASKYN product order forms already received, the company is actively scheduling treatments for eligible patients.
Expanding Treatment Network: The activation of Children’s Hospital Colorado marks a strategic expansion in the QTC network, joining Lurie Children’s Hospital of Chicago and Lucile Packard Children’s Hospital Stanford. Several more centers are in the onboarding process, which is promising for future revenue forecasts.

What This Means for Abeona and Its Peers

The optimistic narrative surrounding Abeona's financial health and operational strategy suggests a potentially bright future for the company. However, the delay in patient treatments pushes the spotlight on how quickly they can ramp up operations without sacrificing quality or safety. Given the growing patient demand, the company's ability to meet this need will be a crucial determinant of its EPS in the next quarter.

For sector peers, Abeona's experience serves as a cautionary tale about the importance of regulatory compliance and the unpredictability of product launches. As companies jockey for position in the competitive landscape of gene therapies, those that can navigate these waters with agility will likely emerge as leaders. Investors should keep a close eye on how Abeona manages the upcoming challenges, as it could set the tone for the broader market.